Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 783-790

  Cairncross, J Gregory ^a   Wang, Meihua ^d   Jenkins, Robert B ^e   Shaw, Edward G ^f   Giannini, Caterina ^e   Brachman, David G ^g   Buckner, Jan C ^e   Fink, Karen L ^h   Souhami, Luis ^b   Laperriere, Normand J ^c   Huse, Jason T ⁱ   Mehta, Minesh P ^j   Curran Jr , Walter J ^k  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d AMERICAN COLLEGE OF RADIOLOGY   (United States)

^e MAYO CLINIC   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g Arizona Oncology Services   (United States)

^h BAYLOR UNIVERSITY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; PROCARBAZINE; VINCRISTINE; ISOCITRATE DEHYDROGENASE;

ADULT; AGE; ALLELE; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; THERAPY EFFECT; WILD TYPE; BRAIN TUMOR; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; HUMANS; INDIVIDUALIZED MEDICINE; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; OLIGODENDROGLIOMA; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84899760157     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.3726     Document Type: Article

References (47)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
2. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
3. Levin VA, Edwards MS, Wright DC, et al: Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-244, 1980
4. Cairncross G, Wang M, Shaw E, et al: A phase 3 trial of chemo-radiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013
5. van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol 31:344-350, 2013
6. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myelogenous leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
7. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
8. Jenkins RB, Wrensch MR, Johnson D, et al: Distinct germline polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 204:13-18, 2011
9. Jenkins RB, Xiao Y, Sicotte H, et al: A low frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumours and IDH1 or IDH2 mutated astrocytomas. Nat Genet 44:1122-1125, 2012
10. Cairncross G, Berkey B, Shaw E, et al: A phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
11. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastro-cytomas. J Clin Oncol 18:636-645, 2000 (Pubitemid 30078545)
12. Heaphy CM, de Wilde RF, Jiao Y, et al: Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425, 2011
13. Casella G, Berger R: Statistical Inference (ed 2). Pacific Grove, CA, Duxbury Press, 2001
14. Harrell FE Jr: Regression Modeling Strategies. New York, NY, Springer, 2001
15. Reifenberger J, Reifenberger G, Liu L, et al: Molecular analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994 (Pubitemid 24345665)
16. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998 (Pubitemid 28482012)
17. Labussière M, Idbaih A, Wang XW, et al: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890, 2010
18. Bettegowda C, Agrawal N, Jiao N, et al: Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-1455, 2011
19. Yip S, Butterfield YS, Morozova O, et al: Concurrent CIC mutations, IDH mutations and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7-16, 2012
20. Killela PJ, Reitman ZJ, Jiao Y, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026, 2013
21. Jiao Y, Killela PJ, Reitman ZJ, et al: Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-722, 2012
22. Noushmehr H, Weisenberger D, Diefes K, et al: Identification of a CpG island methyl-ator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
23. Christensen BC, Smith AA, Zeng S, et al: DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103:143-153, 2011
24. Xu W, Yang H, Liu Y, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30, 2010
25. Ducray F, Idbaih A, de Reyniès A, et al: Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7:41, 2008
26. Cooper LA, Gutman DA, Long Q, et al: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 5:e12548, 2010
27. Verhaak RGW, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by anomalies of PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98-110, 2010
28. Möllemann M, Wolter M, Felsberg J, et al: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005 (Pubitemid 40038704)
29. Blough MD, Al-Najjar M, Chesnelong C, et al: DNA hypermethylation and 1p loss silence NHE-1 in oligodendroglioma. Ann Neurol 71:845-849, 2012
30. Whittemore AS, Gong G, John EM, et al: Prevalence of BRCA1 mutation carriers among US non-Hispanic whites. Cancer Epidemiol Biomarkers Prev 13:2078-2083, 2004 (Pubitemid 40054301)
31. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases: Anglian Breast Cancer Study Group. Br J Cancer 83:1301-1308, 2000
32. CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182, 2004
33. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988 (Pubitemid 18098242)
34. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574, 1990 (Pubitemid 20149980)
35. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine and vincristine (PCV) chemotherapy for grade III and IV oligoastrocytomas. J Neurosurg 85:602-607, 1996 (Pubitemid 26315193)
36. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994 (Pubitemid 24356016)
37. van den Bent MJ, Kros JM, Heimens JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy: Dutch Neuro-oncology Group. Neurology 51:1140-1145, 1998 (Pubitemid 28473415)
38. Chinot OL, Honore S, Dufour H, et al: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449-2455, 2001 (Pubitemid 32391216)
39. van den Bent MJ, Taphoorn MJB, Brandes AA, et al: Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organisation for the Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528, 2003 (Pubitemid 46606334)
40. Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas and oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138, 2004 (Pubitemid 41103727)
41. Giannini C, Burger PC, Berkey BA, et al: Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p/19q codeletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369, 2008 (Pubitemid 351782844)
42. Turcan S, Rohle D, Goenka A, et al: IDH1 mutation is sufficient to establish the hypermethylator phenotype. Nature 483:479-483, 2012
43. van den Bent MJ, Dubbink HJ, Yannick M, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumours: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604, 2010
44. Duncan T, Trewick SC, Koivisto P, et al: Reversal of DNA alkylation damage by two human dioxygenases. Proc Natl Acad Sci U S A 99:16660-16665, 2002 (Pubitemid 36034029)
45. van den Bent MJ, Gravendeel LA, Gorlia T, et al: A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial tumours: A report from the EORTC study 26951. Clin Cancer Res 17:7148-7155, 2011
46. Erdem-Eraslan L, Gravendeel L, de Rooi J, et al: Intrinsic molecular subsets of glioma are prognostic and predictive of benefit from adjuvant procarbazine, lomustine and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: A report from the EORTC study 26951. J Clin Oncol 31:328-336, 2013
47. Theeler BJ, Yung WK, Fuller GN, et al: Moving toward molecular classification of diffuse gliomas in adults. Neurology 79:1917-1926, 2012